Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

NCT06561399 · clinicaltrials.gov ↗

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy

Sponsor

Fujian Provincial Hospital